These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23871444)

  • 1. Attacking cancer with molecularly targeted agents.
    Santoro M; Carlomagno F
    Curr Opin Pharmacol; 2013 Aug; 13(4):483-5. PubMed ID: 23871444
    [No Abstract]   [Full Text] [Related]  

  • 2. Combining targeted drugs to stop resistant tumors.
    Kaiser J
    Science; 2011 Mar; 331(6024):1542-5. PubMed ID: 21436437
    [No Abstract]   [Full Text] [Related]  

  • 3. Somatic alterations as the basis for resistance to targeted therapies.
    Blair BG; Bardelli A; Park BH
    J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapy: overcoming drug resistance with clinical cancer genome.
    Ziogas DE; Katsios CS; Tzaphlidou M; Roukos DH
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):861-4. PubMed ID: 22845399
    [No Abstract]   [Full Text] [Related]  

  • 5. Cancer and natural selection.
    Fillon M
    J Natl Cancer Inst; 2012 Dec; 104(23):1773-4. PubMed ID: 23213180
    [No Abstract]   [Full Text] [Related]  

  • 6. From traditional molecular biology to network oncology.
    Ziogas DE; Katsios C; Roukos DH
    Future Oncol; 2011 Feb; 7(2):155-9. PubMed ID: 21345133
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of acquired resistance to targeted cancer therapies.
    Lackner MR; Wilson TR; Settleman J
    Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel Mechanisms of Resistance to Investigational Molecularly Targeted Drugs].
    Noguchi K
    Yakugaku Zasshi; 2017; 137(2):151-160. PubMed ID: 28154324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the Pathways of Resistance to Targeted Therapies.
    Wood KC
    Cancer Res; 2015 Oct; 75(20):4247-51. PubMed ID: 26392071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preface: National Cancer Act.
    Smalley KS
    Adv Pharmacol; 2012; 65():xi-xiii. PubMed ID: 22959037
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecularly targeted therapies: mechanisms of resistance. Abstracts of the AACR (American Association for Cancer Research) Special Conference. May 9-12, 2012. San Diego, California, USA.
    Clin Cancer Res; 2012 May; 18(10 Suppl):A1-68, B1-68, IA1-15, PR1-8. PubMed ID: 23534065
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecularly targeted cancer therapy: some lessons from the past decade.
    Huang M; Shen A; Ding J; Geng M
    Trends Pharmacol Sci; 2014 Jan; 35(1):41-50. PubMed ID: 24361003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer.
    Izar B; Rotow J; Gainor J; Clark J; Chabner B
    Pharmacol Rev; 2013; 65(4):1351-95. PubMed ID: 24092887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. At the crossroads of cancer stem cells and targeted therapy resistance.
    Wang A; Qu L; Wang L
    Cancer Lett; 2017 Jan; 385():87-96. PubMed ID: 27816488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose determination for molecularly targeted therapies: Much Ado About Nothing.
    Tolcher A
    Cancer; 2017 Apr; 123(8):1298-1300. PubMed ID: 28182254
    [No Abstract]   [Full Text] [Related]  

  • 17. New hopes in the fight against cancer: a special issue on targeted anti-cancer drug discovery and cell signaling.
    Cheng X
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):1-2. PubMed ID: 26578705
    [No Abstract]   [Full Text] [Related]  

  • 18. EGFR-targeted therapy.
    Vecchione L; Jacobs B; Normanno N; Ciardiello F; Tejpar S
    Exp Cell Res; 2011 Nov; 317(19):2765-71. PubMed ID: 21925171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next?
    Bellail AC; Hao C
    Expert Rev Anticancer Ther; 2012 May; 12(5):547-9. PubMed ID: 22594889
    [No Abstract]   [Full Text] [Related]  

  • 20. Overcoming cancer resistance.
    Cook KL; Clarke R
    Future Med Chem; 2015 Aug; 7(12):1471. PubMed ID: 26334204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.